Reported Tuesday, May 5 - 8:07am EDT (TheFly subscription required to read more.)

Johnson & Johnson announces promising Phase 2b results for their co-antibody therapy JNJ-4804, targeting stubborn inflammatory bowel diseases.

Johnson & Johnson (NYSE: JNJ) reported Phase 2b DUET-UC and DUET-CD results for JNJ-4804, an investigational co-antibody targeting IL-23 and TNF-α. At Week 48 the JNJ-4804 high-dose group showed higher clinical remission and endoscopic response rates versus golimumab and numerically higher rates versus guselkumab in UC and CD.JNJ will advance JNJ-4804 into Phase 3 DUET ENCORE-CD and DUET ENCORE-UC trials; safety was described as generally consistent with known monotherapy profiles.

Royalty Pharma (Nasdaq: RPRX) announced a research and development co-funding agreement with Johnson & Johnson totaling $500 million across 2026 and 2027 to advance JNJ-4804, an investigational co-antibody targeting IL-23 and TNF for chronic immune-mediated diseases.The collaboration funds clinical development of JNJ-4804 and aligns Royalty Pharma with a major immunology partner while advisors Goodwin Procter served as legal counsel.

Die Johnson & Johnson Aktie (ISIN: US4781601046) profitiert von einer neuen R&D-Finanzierung mit Royalty Pharma in Höhe von 500 Millionen US-Dollar für die Entwicklung von JNJ-4804 gegen Autoimmunerkrankungen. Anleger in Deutschland, Österreich und der Schweiz schätzen die Zuverlässigkeit des Konzerns als defensives Investment. Nächste Quartalszahlen am 14. April im Blick.

The combination showed efficacy exceeding that of either monotherapy

JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to two or more systemic therapy classes JNJ-4804 is the first and only fixed dose...

This edition of Immunology Updates highlights major regulatory and clinical developments across autoimmune and inflammatory diseases. Bristol Myers Squibb received EU approval for Sotyktu in active psoriatic arthritis, while Mabwell secured FDA IND clearance for 9MW5211 in inflammatory bowel disease. Artiva reported positive AlloNK data and FDA alignment for a Phase 3 rheumatoid arthritis trial. Johnson & Johnson advanced JNJ-4804 in refractory IBD, while emerging in vivo CAR and CAR-M programs from CREATE Medicines and Liberate Bio continued to expand immune-programming innovation.

This biweekly Immunology video recap highlights regulatory progress, autoimmune pipeline expansion, positive clinical data, and advancing cell-therapy platforms. 🔬 Key Highlights: 🧬 Mabwell 9MW5211 FDA IND clearance 💊 Sotyktu EU approval in active psoriatic arthritis 🧫 Artiva AlloNK Phase 3 alignment in refractory RA 🦠 JNJ-4804 Phase 2b IBD data 🧪 Regeneron fianlimab Phase 3 melanoma update 🧬 Fate FT819 lupus nephritis trial plans 💰 CREATE Medicines Series B financing 🧫 Liberate Bio LIB820 preclinical CAR-M data Chapters: 0:00 Introduction 0:09 Mabwell 9MW5211 FDA IND clearance 0:34 Sotyktu EU approval in active psoriatic arthritis 1:01 Artiva AlloNK Phase 3 alignment in refractory RA 1:34 JNJ-4804 Phase 2b IBD data 1:59 Regeneron fianlimab Phase 3 melanoma update 2:26 Fate FT819 lupus nephritis trial plans 2:53 CREATE Medicines Series B financing 3:15 Liberate Bio LIB820 preclinical CAR-M data 3:39 How to reach us 📢 Stay Ahead in Immunology Research! ✅ Like, share, and subscribe for future updates on Immunology ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Immunology innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #Immunology #FDA #PsoriaticArthritis #IBD #AutoimmuneDisease #ClinicalTrials #CellTherapy #Biotech #PharmaNews #LucidQuest

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804 Professional audiences only. Not investment […] The post Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804 appeared first on LucidQuest Ventures.